More Articles Back to Article
Dosing initiated for Russia's second COVID-19 vaccine
The Vector virology institute in Russia has launched human trials for its second experimental COVID-19 vaccine through the dosing of the first volunteer on July 27, according to an RIA news agency report. The vaccine uses a platform previously developed for Ebola and will enroll up to 100 volunteers aged 18 and 60. World Health Organization records indicate that Vector is developing six potential COVID-19 vaccines. Reuters (7/28)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!